Pharmaceutical spend continues to be a main cost driver in the health care system, while additional governmental regulations challenge payers and providers. Despite factors in the marketplace that are out of our control, we are proud to have delivered a single-digit drug trend rate to our clients in 2015, based on total cost.
Learn more about all of the efforts Navitus has in place today to counter drug trend.
Virtus Pharmaceuticals Opco II, LLC is voluntarily recalling 7 batches of Hyoscyamine sulfate 0.125mg to the consumer level which include the tablet, sublingual, and orally disintegrating tablet form.
Novo Nordisk Inc. is recalling six batches of the GlucaGen HypoKit in the U.S. due to two customer complaints from the UK and Portugal involving detached needles on the syringe with Sterile Water for Injection.
Contact Us | Careers | MedicareRx (PDP) | Navi-Gate Rx | Site Map | Confidentiality Statement | Vendor/FDR | Download Adobe Reader